ISAL 2019 | Translating epigenetic therapy to the clinic: rational combinations
Ari Melnick
Ari Melnick, MD, of Weill Cornell Medical College, New York, NY, discusses the layers of complexity surrounding the epigenome in acute leukemias, which must be better understood in order to more effectively design and utilize epigenetic therapies. He highlights the importance of rational combinations, referencing research using azacitidine with an LSD1 inhibitor on an organoid culture system of primary specimens of acute myeloid leukemia (AML). This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
Related videos
An exciting era for CAR T-cell therapy
Mohamad Mohty
Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno
JCAR017 for relapsed/refractory CLL
Tanya Siddiqi
Combining novel agents for CLL to achieve deep remissions: time-limited therapy, treatment cessation & drug re-use in relapse
Talha Munir
